Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 26;9(5):428. doi: 10.3390/nu9050428

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Percent changes of serum bone-specific alkaline phosphatase (BAP) (a); serum N-terminal propeptide of type 1 procollagen (P1NP) (b); serum tartrate-resistant acid phosphatase (TRACP)-5b (c); urinary cross-linked N-terminal telopeptides of type I collagen (NTX) (d) over the 12-month study period. Closed circles show the denosumab monotherapy group and closed triangles show the combination group. Single asterisk (*) denotes significant differences (p < 0.05) and double asterisks (**) denote significant differences (p < 0.01) at each time point compared with pretreatment in the denosumab monotherapy or combination groups. Single hashtag (#) shows significant differences (p < 0.05) and double hashtags (##) show significant differences (p < 0.01) between the denosumab monotherapy and combination groups at each time point.

Percent changes of serum bone-specific alkaline phosphatase (BAP) (a); serum N-terminal propeptide of type 1 procollagen (P1NP) (b); serum tartrate-resistant acid phosphatase (TRACP)-5b (c); urinary cross-linked N-terminal telopeptides of type I collagen (NTX) (d) over the 12-month study period. Closed circles show the denosumab monotherapy group and closed triangles show the combination group. Single asterisk (*) denotes significant differences (p < 0.05) and double asterisks (**) denote significant differences (p < 0.01) at each time point compared with pretreatment in the denosumab monotherapy or combination groups. Single hashtag (#) shows significant differences (p < 0.05) and double hashtags (##) show significant differences (p < 0.01) between the denosumab monotherapy and combination groups at each time point.